Compare BTGO & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTGO | STTK |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 806.4M | 792.9M |
| IPO Year | 2025 | 2020 |
| Metric | BTGO | STTK |
|---|---|---|
| Price | $6.95 | $6.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $14.83 | $10.00 |
| AVG Volume (30 Days) | ★ 1.7M | 848.5K |
| Earning Date | 05-13-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $34.41 | N/A |
| P/E Ratio | $10.81 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.65 | $1.19 |
| 52 Week High | $15.30 | $8.33 |
| Indicator | BTGO | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 63.09 | 48.50 |
| Support Level | $4.70 | $6.93 |
| Resistance Level | $12.11 | $7.75 |
| Average True Range (ATR) | 0.46 | 0.35 |
| MACD | 0.07 | -0.10 |
| Stochastic Oscillator | 75.82 | 29.86 |
BitGo Holdings Inc provides various offerings to its clients including multi-signature blockchain wallet solutions allowing for secure storage, trade settlement, staking solutions, and lending of digital assets. The Company also provides professional services to develop smart contracts. Its clients range from crypto-native companies that use its self-custody wallet technology to traditional financial services firms that leverage its licensed custody, staking and trading capabilities within their own products and services.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.